We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




VOCs Show Promise for Early Multi-Cancer Detection

By LabMedica International staff writers
Posted on 01 Oct 2025

Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. More...

This makes it difficult to identify tumors across multiple organs at an early stage. Researchers have now demonstrated that chemical “scents” released by the body could serve as reliable markers for detecting cancer earlier and more broadly, providing a foundation for multi-cancer (pan-cancer) screening.

A team of researchers at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (HFIPS-CAS, Hefei, China) has developed a method that uses volatile organic compounds (VOCs) as potential biomarkers for cancer. For their study, the researchers established a pan-cancer mouse model by chemically inducing tumors in organs such as the lungs, stomach, liver, and esophagus. They then collected urine, feces, and odor samples over a 21-week tumor development period for detailed analysis.

Using headspace solid-phase microextraction gas chromatography-mass spectrometry (HS-SPME-GC-MS), the team performed non-targeted detection of VOCs. The results revealed three sets of tumor-associated compounds that reflected metabolic changes during cancer progression. The study, published in the Journal of Proteome Research, shows that VOCs could effectively distinguish tumor-bearing mice from healthy controls.

Notably, early tumor signals were detectable well before advanced cancer development, appearing in urine at week 5, in odor at week 13, and in feces at week 17. These findings suggest that VOCs can act as early indicators of tumor activity, offering new opportunities for non-invasive screening. The study provides an important experimental framework for applying VOC-based biomarkers in future pan-cancer research.

This approach has the potential to expand screening beyond single cancers, enabling detection across multiple organs simultaneously. If adapted for human use, it could support earlier interventions and reduce reliance on invasive tests, making screening more accessible and effective. Future research will focus on refining VOC detection methods and translating these findings into clinical applications.

Related Links:
HFIPS-CA


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.